• 1
    Fontaine GL, Belknap JK, Allen D., et al. Expression of interleukin-1 beta in the digital laminae of horses in the prodromal stage of experimentally induced laminitis. Am J Vet Res 2001;62:714720.
  • 2
    Waguespack RW, Kemppainen RJ, Cochran A., et al. Increased expression of MAIL, a cytokine-associated nuclear protein, in the prodromal stage of black walnut-induced laminitis. Equine Vet J 2004;36:285291.
  • 3
    Hinz B., Brune K. Pain and osteoarthritis: new drugs and mechanisms. Curr Opin Rheumatol 2004;16:628633.
  • 4
    Keller SA, Paxian M., Lee SM, et al. Kupffer cell ablation attenuates cyclooxygenase-2 expression after trauma and sepsis. J Surg Res 2005;124:126133.
  • 5
    Lees P., Landoni MF, Giraudel J., et al. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. J Vet Pharmacol Ther 2004; 27:479490.
  • 6
    Kis B., Snipes JA, Busija DW. Acetaminophen and the COX-3 Puzzle: Sorting out Facts, Fictions and Uncertainties. J Pharmacol Exp Ther 2005;315:17.
  • 7
    Chandrasekharan NV, Dai H., Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:1392613931.
  • 8
    Davies NM, Good RL, Roupe KA, et al. Cyclooxygenase-3: aAxiom, dogma, anomaly, enigma or splice error?—Not as easy as 1, 2, 3. J Pharm Pharm Sci 2004;7:217226.
  • 9
    Snipes JA, Kis B., Shelness GS, et al. Cloning and characterization of cyclooxygenase-1b (putative cyclooxygenase-3) in rat. J Pharmacol Exp Ther 2005;313:668676.
  • 10
    Yan Z., Stapleton PP, Freeman TA, et al. Enhanced expression of cyclooxygenase-2 and prostaglandin E2 in response to endotoxin after trauma is dependent on MAPK and NF-kappaB mechanisms. Cell Immunol 2004;232:116126.
  • 11
    Parks A., O'Grady SE. Treatment of acute laminitis. Equine Veterinary Education 2003;15:273280.
  • 12
    MacAllister CG, Taylor-MacAllister C. Treating and preventing the adverse effects of nonsteroidal anti-inflammatory drugs in horses. Veterinary Medicine 1994;89:241246.
  • 13
    Morton AJ, Campbell NB, Gayle JM, et al. Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis. Res Vet Sci 2005; 78:189192.
  • 14
    Waguespack RW, Cochran A., Belknap JK. Expression of the cyclooxygenase isoforms in the prodromal stage of black walnut-induced laminitis in horses. Am J Vet Res. 2004; 65: 17241729.
  • 15
    Wilson JE, Chandrasekharan NV, Westover KD, et al. Determination of expression of cyclooxygenase-1 and-2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 2004;65:810818.
  • 16
    Leong J., Hughes-Fulford M., Rakhlin N., et al. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Exp Cell Res 1996;224:7987.
  • 17
    Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997;49(Suppl):1519.
  • 18
    Peskar BM, Maricic N., Gretzera B., et al. Role of cyclooxygenase-2 in gastric mucosal defense. Life Sci 2001; 69:29933003.
  • 19
    Anderson GD, Hauser SD, McGarity KL, et al. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996;97:26722679.
  • 20
    Kang RY, Freire-Moar J., Sigal E., et al. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 1996;35:711718.
  • 21
    Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790804.
  • 22
    Bulut D., Liaghat S., Hanefeld C., et al. Selective cyclooxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens 2003;21:16631667.
  • 23
    Mizuno H., Sakamoto C., Matsuda K., et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387397.
  • 24
    Lee JL, Mukhtar H., Bickers DR, et al. Cyclooxygenases in the skin: Pharmacological and toxicological implications. Toxicol Appl Pharmacol 2003;192:294306.
  • 25
    Kotnik P., Nielsen J., Kwon TH, et al. Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol 2005: 288: F10531068.
  • 26
    Orman B., Reina S., Borda E., et al. Signal transduction underlying carbachol-induced PGE2 generation and cox-1 mRNA expression of rat brain. Neuropharmacology 2005;48:757765.
  • 27
    Keen JA, McLaren M., Chandler KJ, et al. Equine laminitis: loss of hemidesmosomes in hoof secondary epidermal lamellae correlates to dose in an oligofructose induction model: an ultrastructural study. Equine Vet J 2004;36:226229.
  • 28
    Bishop-Bailey D., Pepper JR, Larkin SW, et al. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol 1998;18:16551661.
  • 29
    Allen D. Jr, Clark ES, Moore JN, et al. Evaluation of equine digital Starling forces and hemodynamics during early laminitis. Am J Vet Res 1990;51:19301934.
  • 30
    Rupp J., Berger M., Reiling N., et al. Cox-2 inhibition abrogates Chlamydia pneumoniae-induced PGE2 and MMP-1 expression. Biochem Biophys Res Commun 2004;320:738744.
  • 31
    Ito H., Duxbury M., Benoit E., et al. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 2004;64:74397446.
  • 32
    Kyaw-Tanner M., Pollitt CC. Equine laminitis: Increased transcription of matrix metalloproteinase-2 (MMP-2) occurs during the developmental phase. Equine Vet J 2004;36:221225.
  • 33
    Johnson PJ, Kreeger JM, Keeler M., et al. Serum markers of lamellar basement membrane degradation and lamellar histopathological changes in horses affected with laminitis. Equine Vet J 2000;32:462468.
  • 34
    Buerkle MA, Lehrer S., Sohn HY, et al. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 2004;110:20532059.
  • 35
    Moppett IK, Davies JA, Mahajan RP. Non-selective and cyclo-oxygenase-2-specific non-steroidal anti-inflammatory drugs impair the hyperaemic response of skin to brief axillary artery occlusion. Br J Anaesth 2003;91:353356.
  • 36
    Krotz F., Schiele TM, Klauss V., et al. Selective COX-2 Inhibitors and Risk of Myocardial Infarction. J Vasc Res 2005;42:312324.
  • 37
    Evans CB, Pillai S., Goldyne ME. Endogenous prostaglandin E2 modulates calcium-induced differentiation in human skin keratinocytes. Prostaglandins Leukot Essent Fatty Acids 1993; 49:777781.
  • 38
    Shao J., Sheng H., Inoue H., et al. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 2000;275:3395133956.
  • 39
    Dixon DA, Kaplan CD, McIntyre TM, et al. Posttranscriptional control of cyclooxygenase-2 gene expression. The role of the 3-untranslated region. J Biol Chem 2000; 275: 1175011757.
  • 40
    Ichitani Y., Holmberg K., Maunsbach AB, et al. Cyclooxygenase-1 and cyclooxygenase-2 expression in rat kidney and adrenal gland after stimulation with systemic lipopolysaccharide: in situ hybridization and immunocytochemical studies. Cell Tissue Res 2001;303:235252.
  • 41
    Camu F., Shi L., Vanlersberghe C. The role of COX-2 inhibitors in pain modulation. Drugs 2003;63(Suppl 1):17.
  • 42
    Goodwin DC, Landino LM, Marnett LJ. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J 1999;13:11211136.
  • 43
    Parfenova H., Balabanova L., Leffler CW. Posttranslational regulation of cyclooxygenase by tyrosine phosphorylation in cerebral endothelial cells. Am J Physiol 1998;274:C7281.